Jimmie Harvey
Hematology & Oncology · Birmingham, ALNPI 1801813357
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,100 and has fallen 97.5% since, to $27 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AL, where the typical reported total is $7,159.
Across 85 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$226
- Novartis$223
- Johnson & Johnson$178
- Pfizer$159
- Amgen$66
- AstraZeneca$51
- plus $401 from 19 others
Across 38 payments — averaging $23.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$882
What the payments were for
- Food & beverage$1,26897%
- Education$353%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 14 | $226 |
| Novartis | 12 | $223 |
| Johnson & Johnson(2 entities) | 13 | $178 |
| Pfizer | 12 | $159 |
| Amgen | 4 | $66 |
| AstraZeneca(2 entities) | 3 | $51 |
| Rigel Pharmaceuticals, Inc. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Bristol Myers Squibb | 2 | $37 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Array Biopharma Inc | 2 | $24 |
| Sanofi | 1 | $23 |
| Boehringer Ingelheim | 1 | $19 |
| Exelixis Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Bayer | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| GSK | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
| Gilead | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
| Clovis Oncology, Inc. | 1 | $4 |
How this compares
$1,303 in reported general payments places this provider in the 20th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Birmingham
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.